A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine2009Vol. 361(21), pp. 2019–2032
Citations Over TimeTop 1% of 2009 papers
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto
Abstract
The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)
Related Papers
- → Darbepoetin Alfa(2001)66 cited
- → Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open‐label, Australian study(2007)19 cited
- [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].(2002)
- → Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia*(2002)7 cited
- → Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy‐induced anemia(2006)6 cited